October 24, 2017 / 7:44 AM / in a month

BRIEF-Rovi announces update on risperidone project

Oct 24 (Reuters) - LABORATORIOS FARMACEUTICOS ROVI SA :

* ANNOUNCES UPDATE ON A PHASE III STUDY FOR A LONG-ACTING INJECTABLE (LAI) TO TREAT SCHIZOPHRENIA CALLED DORIA(PREVIOUSLY RISPERIDONE ISM)

* SEES NEW DRUG APPLICATION (NDA) AND MARKETING AUTHORIZATION APPLICATION (MAA) OF DORIA IN 2019-2020

* SEES POTENTIAL ALTERNATIVE: PHASE III (PRISMA-4) MAINTENANCE EFFICACY STUDY OF DORIA IN 2019-2020

* COMPANY WILL NEED R&D INVESTMENT FOR THE COMING YEARS, TO DEVELOP DORIA PHASE III TOGETHER WITH LETROZOLE ISM PHASE I

* SEES 2017-2019 AVERAGE COST OF R&D OF ABOUT 32 MILLION EUROS PER YEAR

* SAYS IN THE PERIOD 2020-2021, THIS AVERAGE DECREASES TO 22 MILLION EUROS PER YEAR

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below